Betterway Medtech secures RMB ~100M in Series B funding to accelerate innovation in peripheral vascular and heart failure markets

Recently, Betterway Medtech announced the completion of a nearly RMB 100 million Series B financing round. This round was led by Tasly Capital, with participation from Triwise, and WinX Capital acted as the exclusive financial advisor. The proceeds from this financing round will be primarily utilized for new product research and development, the construction of a production base, and market expansion, thereby accelerating Betterway Medtech's development of innovative product portfolios in the fields of peripheral vascular intervention and heart failure.

In the peripheral vascular intervention field, Betterway Medtech has established a comprehensive product matrix encompassing "debulking, thrombectomy, and access" technologies, with multiple technologies holding a leading position within China. Several of its devices represent domestic breakthroughs and have successfully obtained marketing approval in China. Concurrently, a larger number of innovative products have entered the clinical application and registration phases, building a full-cycle, sustainable product development and launch system.

Betterway Medtech's independently developed Peripheral Venous Thrombectomy System is the only innovative product in its category in China to have been granted access to the "Green Channel for Special Review and Approval of Innovative Medical Devices". This product's multi-center registration clinical trial in China was led by Chief Physician Lu Xinzheng from the Department of Vascular Surgery at Shanghai Ninth People's Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and it is nearing market approval in China. Furthermore, Betterway Medtech's Pulmonary Embolism Thrombectomy System, which received marketing approval in China in 2025, is the country's only self-expanding stent-retriever thrombectomy system. It is directly comparable to the design of second-generation international competitor products and possesses fully independent intellectual property rights. Simultaneously, Betterway Medtech is strategically developing products for arterial thrombus debulking, aiming to establish itself as the premier brand for the physical debulking of intravascular thrombi within China.

 Pulmonary Artery Thrombectomy System

Peripheral Venous Thrombectomy System

Focusing on heart failure, often described as the "last frontier" in the battle against cardiovascular disease, Betterway Medtech is developing comprehensive medical device solutions for heart failure and its related complication syndromes. A key area of focus is its atrial shunt system, which aims to fill a gap in this specific therapeutic area within China. Currently, only a few companies globally are active in the atrial shunt field, and Betterway Medtech is among the first in China to have entered the clinical stage. Betterway Medtech anticipates developing the first atrial shunt system in China and aims to create the world's first implant-free atrial shunt system. Concurrently, Betterway Medtech is continuously expanding its product line related to heart failure diagnosis and treatment, developing multiple innovative devices to build a complete solution encompassing diagnosis, treatment, and monitoring.

Leveraging its self-developed technology platforms and its capability to integrate cross-disciplinary technologies, Betterway Medtech has established a significant first-mover advantage in the peripheral intervention and heart failure sectors. Betterway Medtech consistently introduces high-quality new products, steadily advances their path to market, and continuously enriches its product matrix to enhance market supply. Through a steady stream of innovative achievements, it meets market demands and user needs, providing solid support for its long-term, stable business development.